We are delighted to announce that Bellberry, ACTA, NHMRC CTC and The George Institute have formed a consortium ‘Clinical Trials: Impact & Quality (CT:IQ)’.
The consortium’s mission is “to develop and implement recommendations that will improve the impact, quality and efficiency of clinical trials, leading to more rapid, lower cost and higher quality evaluation of healthcare interventions in Australia”. CT:IQ will drive performance and impact improvements in Australian Clinical Trials; together we will be Thinking Smarter about Clinical Trials.
CT:IQ is modelled on the highly successful US FDA-funded Clinical Trials Transformation Initiative (CTTI). The pilot project is co-funded by MTPConnect and has commitment from a range of organisations and stakeholders from the Australian Clinical Trials sector.
CT:IQ will be formally launched by Minister Hunt and Minister Cash on Wednesday 16 May at the Royal Melbourne Hospital from 10.30am. This event is also a collaborative effort and will launch CT:IQ, celebrate the ACTA Clinical Trial of the Year Awards and launch the NHMRC consumer engagement campaign. This will be followed by a CT:IQ lunchtime symposium. Registration is free but numbers are strictly limited: https://acta_awards_2018.eventbrite.com.au
For more information, contact Programme Manager Rebecca Trowman at rebeccatrowman@bellberry.com.au